ALLO vs AME · rev $22.0K vs P/E 30, rev $7.40B
Allogene Therapeutics Inc (ALLO) versus Ametek Inc (AME) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
Ametek Inc (AME) is a specialty industrial machinery company listed on US.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported AME revenue for 2025-12-31 was $7.40B. Net income was $1.48B. Revenue was up 6.6% from 2024-12-31 to 2025-12-31. AME currently screens at market cap $42.11B and trailing P/E 29.9.
ALLO currently screens at market cap $258.1M. AME currently screens at market cap $42.11B and trailing P/E 29.9.
Not investment advice. Open the ALLO and AME stock pages for the full models.
Not investment advice.